awmsg logo



rufinamide (Inovelon®)


Reference No. 1663

Publication date:
25/10/2012


Last review date:
30/08/2016

Appraisal information

rufinamide (Inovelon®) 40 mg/ml oral suspension


Company: Eisai Ltd
BNF category: Central nervous system
NMG meeting date: 10/07/2012
AWMSG meeting date: 12/09/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3312
Ministerial ratification: 25/10/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Rufinamide (Inovelon®) 40 mg/ml oral suspension is recommended as an option for use within NHS Wales as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of age and older where other adjunctive treatments have proved sub-optimal or have not been tolerated.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download